Get access to Hummingbird’s Mirna Biomarker Platform
Partnering
Enhanced clinical drug development
- Disease & treatment monitoring marker
- Immunological status
- Toxicological & adverse event marker
Diagnostic development
- Early diagnosis
- Prognosis
- Companion
Access to ip portfolio
- Out-licensing
- Co-development
Interested in collaboration?
Please contact us!
Get access to Hummingbird’s Mirna Biomarker Platform
IP
Dominant IP in whole blood
- 29 patent families
- Encompassing all major disease groups
- Seventeen patents granted
- Barrier to new entrants
Access to ip portfolio
- Out-licensing
- Co-development
Hummingbird’s contribution to grants
Grants
Validation of clinical biomarkers
Hummingbird is a premier and reliable partner with focus on discovery and validation of clinical biomarkers, including Quality assurance, RNA extraction, microRNA/mRNA Analysis, Bioinformatics
Hummingbird has experience as partner in 3 European FP7-funded consortia:
- BestAgeing
- RiskyCAD
- EURenOmics
Contact
Are you looking for a SME or Subcontractor as partner for your project proposal? Please contact us!
Contact